FLT3 and acute myeloid leukemia: On the basis of the outcomes from this pivotal phase 3 trial (RATIFY), midostaurin (in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation therapy) was approved by the US Food and Drug Administration (FDA) in April 2017 for the treatment of adult patients with newly diagnosed FLT3-mutated AML as detected by an FDA-approved test [71, 72].